Febrile Neutropenia with Pembrolizumab Monotherapy is Extremely Rare
Pembrolizumab monotherapy carries a very low risk of febrile neutropenia, with rates of 0% reported in major clinical trials. This stands in stark contrast to pembrolizumab combined with chemotherapy, where febrile neutropenia becomes a significant concern.
Incidence Based on Treatment Regimen
Pembrolizumab Monotherapy
The risk of febrile neutropenia with pembrolizumab alone is negligible. In the KEYNOTE-119 trial of pembrolizumab monotherapy for metastatic triple-negative breast cancer, neutropenia of any grade occurred in 0% of patients 1. Similarly, in KEYNOTE-012 for head and neck cancer, serious adverse reactions occurred in 45% of patients, but febrile neutropenia was not among the commonly reported events 2.
Pembrolizumab Plus Chemotherapy
When pembrolizumab is combined with chemotherapy, febrile neutropenia becomes clinically relevant:
KEYNOTE-355 (pembrolizumab + chemotherapy for triple-negative breast cancer): Grade 3-4 neutropenia occurred in 30% of patients in both the pembrolizumab-chemotherapy and placebo-chemotherapy arms, indicating the neutropenia risk is driven by chemotherapy rather than pembrolizumab 1
KEYNOTE-522 (neoadjuvant/adjuvant setting for early-stage TNBC): Febrile neutropenia was a serious adverse reaction in 15% of patients, and was the most common reason for treatment interruption (2.8%) 2
KEYNOTE-048 (pembrolizumab + platinum/5-FU for head and neck cancer): Febrile neutropenia occurred in 2.9% of patients receiving the combination, compared to minimal rates with pembrolizumab monotherapy 2
Clinical Context and Mechanism
The mechanism of neutropenia differs fundamentally between monotherapy and combination therapy:
- Chemotherapy-induced neutropenia is predictable, dose-dependent, and occurs early (typically 7-14 days post-administration)
- Immune-mediated neutropenia from pembrolizumab alone is exceedingly rare but can occur at any time, even after 36 cycles of therapy 3
Recent pharmacovigilance data from FAERS identified 856 serious neutropenia cases among 14,747 pembrolizumab-related adverse events, with 86.5% (269/311) of febrile neutropenia cases occurring in patients receiving concomitant chemotherapy 4. The median time-to-onset was 14.5 days with chemotherapy versus 39 days without chemotherapy 4.
Key Clinical Implications
For pembrolizumab monotherapy:
- Routine G-CSF prophylaxis is not indicated
- Standard neutropenic precautions are unnecessary
- If neutropenia develops, consider immune-mediated etiology and perform bone marrow biopsy to exclude alternative causes 3
For pembrolizumab plus chemotherapy:
- Follow standard chemotherapy-related febrile neutropenia protocols
- Risk stratification using MASCC score (≥21 indicates low risk suitable for outpatient management) remains valid 5
- Consider G-CSF support based on chemotherapy regimen risk, not pembrolizumab
- If neutropenia persists beyond expected chemotherapy nadir (>10 days), consider immune-mediated component 5
Important Caveats
While rare, immune-mediated neutropenia from pembrolizumab can be severe and life-threatening when it occurs 6. One case report described grade 3 pancytopenia as part of multiorgan immune toxicity requiring high-dose methylprednisolone 6. The mortality rate in reported neutropenia cases was 19.4%, though this includes combination therapy cases 4.
Bottom line: Pembrolizumab monotherapy poses essentially no risk of febrile neutropenia. The risk emerges only when combined with myelosuppressive chemotherapy, where the chemotherapy—not the immunotherapy—drives the neutropenia risk.